Ionis Pharmaceuticals (IONS) Tops Q3 EPS by 42c, Beats on Revenue; Offers FY25 EPS Guidance
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/23/2026
- S&P, Nasdaq end lower on semiconductor selloff as AI spending concerns mount
- Chip stocks plunge, but bargain-hunters stem losses in other tech names
- Oil prices finish 1% lower as investors focus on Hormuz flows after peace talks
- South Korea leveraged ETF crisis sparks global chip selloff
- Trump announces nuclear deal with Iran, lifts Hormuz blockade
- Exclusive-China robot-hand-building unicorn Linkerbot targets $6 billion valuation
- Spain's ex-transport minister sentenced to 24 years for corruption
- China, US, UAE police arrest 276 telecom fraud suspects in Dubai
- Li Auto Inc. (LI) Breaks Ground on Chips R&D and Production Base
- Needham Starts NeoVolta (NEOV) at Buy
Ionis reports third quarter 2025 financial results and highlights progress on key programs
October 29, 2025 7:00 AM EDT- TRYNGOLZA® generated $32 million in net product sales in the third quarter 2025 -
- DAWNZERA (donidalorsen) launch off to encouraging start -
- Olezarsen significantly reduced triglycerides and acute pancreatitis events in severe hypertriglyceridemia (sHTG) in landmark Phase 3 studies; sNDA submission on track by year-end
- Positive pivotal zilganersen results in Alexander disease position Ionis for first independent neurology launch in 2026 -
- Increasing 2025 financial guidance driven by continued strength across the business
CARLSBAD, Calif.--(BUSINESS WIRE)-- Ionis... More
